MiniMed: High Energy Model for Growth
Executive Summary
MiniMed is riding a wave of success, with its external insulin pump business growing 30% a year, and its continuous glucose monitor in the final stages of the FDA approval process. With so many device companies stumbling in the race to find better ways to treat diabetes, why is MiniMed flourishing?
You may also be interested in...
Alfred Mann: Boundless Innovator
An interview with Alfred Mann, one of the device industry's most remarkable innovators, whose extraordinary technological and commercial successes extend from cardiology to cochlear implants to neurostimulation, and who is now looking to succeed where others have failed with inhaled insulin.
Becton Dickinson, with Heavyweight Helpers, Finally Jumps into Diabetes Testing
Becton Dickinson & Co.'s announcement in January that it is entering the diabetes testing business laid to rest questions about its commitment to a field it has tinkered with for years. The move, however, raised new speculation about the company's ability to make inroads in a market it is entering late and which is dominated by Roche and Johnson & Johnson, who are willing to protect their lucrative shares of the monitoring business with heavy product development and marketing spending.
Becton Dickinson, with Heavyweight Helpers, Finally Jumps into Diabetes Testing
Becton Dickinson & Co.'s announcement in January that it is entering the diabetes testing business laid to rest questions about its commitment to a field it has tinkered with for years. The move, however, raised new speculation about the company's ability to make inroads in a market it is entering late and which is dominated by Roche and Johnson & Johnson, who are willing to protect their lucrative shares of the monitoring business with heavy product development and marketing spending.